Kazuyoshi Shigehara1, Hiroyuki Konaka2, Eitetsu Koh2, Koji Izumi2, Yasuhide Kitagawa2, Atsushi Mizokami2, Takao Nakashima1, Masayoshi Shimamura3, Teruaki Iwamoto4, Mikio Namiki2. 1. a Department of Urology , Ishikawa Prefectural Central Hospital , Kanazawa, Ishikawa , Japan . 2. b Department of Integrative Cancer Therapy and Urology , Kanazawa University Graduate School of Medical Science , Kanazawa, Ishikawa , Japan . 3. c Department of Urology , Nomi City Hospital , Nomi, Ishikawa , Japan , and. 4. d Division of Male Infertility , Center for Infertility and IVF, International University of Health and Welfare , Nasushiobara, Tochigi , Japan.
Abstract
OBJECTIVE: We investigated the effects of testosterone replacement therapy (TRT) on nocturia and general health among men with hypogonadism and nocturia. METHODS: From our previous EARTH study population, 64 patients with a clinical diagnosis of nocturia (two or more times per one night) and hypogonadism, comprising the TRT group (n = 31) and controls (n = 33), were included in this analysis. The TRT group was administered 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 6 months. All patients responded to the following questionnaires: International Prostatic Symptoms Score (IPSS), Aging Male Symptoms (AMS) score and Short Form-36 health survey at baseline and 6-month visit. These categories were compared based on changes from baseline to the 6-month visit between TRT and control groups. RESULTS: At the 6-month visit, the TRT group had a significant decrease in IPSS question no. 7 and AMS question no. 4, whereas no significant changes were observed in the control group. Additionally, role limitation because of health program, vitality and mental health domains were significantly improved in the TRT group. CONCLUSIONS: Six-month TRT may improve nocturia, sleep conditions and quality of life among men with hypogonadism and nocturia.
RCT Entities:
OBJECTIVE: We investigated the effects of testosterone replacement therapy (TRT) on nocturia and general health among men with hypogonadism and nocturia. METHODS: From our previous EARTH study population, 64 patients with a clinical diagnosis of nocturia (two or more times per one night) and hypogonadism, comprising the TRT group (n = 31) and controls (n = 33), were included in this analysis. The TRT group was administered 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 6 months. All patients responded to the following questionnaires: International Prostatic Symptoms Score (IPSS), Aging Male Symptoms (AMS) score and Short Form-36 health survey at baseline and 6-month visit. These categories were compared based on changes from baseline to the 6-month visit between TRT and control groups. RESULTS: At the 6-month visit, the TRT group had a significant decrease in IPSS question no. 7 and AMS question no. 4, whereas no significant changes were observed in the control group. Additionally, role limitation because of health program, vitality and mental health domains were significantly improved in the TRT group. CONCLUSIONS: Six-month TRT may improve nocturia, sleep conditions and quality of life among men with hypogonadism and nocturia.
Entities:
Keywords:
Hypogonadism; nocturia; quality of life; testosterone replacement therapy
Authors: John Wai-Man Yuen; Ivy Yuen-Ping Wong; Peter Ka-Fung Chiu; Jeremy Yuen-Chun Teoh; Chi-Kwok Chan; Chi-Hang Yee; Chi-Fai Ng Journal: Int J Environ Res Public Health Date: 2022-09-15 Impact factor: 4.614
Authors: Guadalupe Vargas-Ortega; Gabriel Pérez-Villarreal; Andrés Ramírez de Santiago; Lourdes Balcázar-Hernández; Victoria Mendoza-Zubieta; Oscar Landa-Gutierrez; Carlos Estrada-Robles; Baldomero González-Virla Journal: Int J Endocrinol Date: 2019-11-03 Impact factor: 3.257